Zydus receives tentative approval from USFDA for Bosentan tablets for oral suspension
Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)
Bosentan Tablets for Oral Suspension had annual sales of USD 16 mn in the United States (IQVIA MAT Dec. 2022)
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya
Olaparib is indicated primarily for certain forms of ovarian, breast, pancreatic, and prostate cancer
Dr. Dietmar Berger, has agreed to take the leadership of the team ad interim
The respective product approval is based on Revlimid Capsules, 5mg, 10mg, 15mg, 25mg and 2.5mg, 20mg as a reference product
The approval for Glycopyrrolate clears the path for more internally manufactured injectable products
The company will engage with the agency to resolve the import alert at the earliest.
Granules now have a total of 53 ANDA approvals from USFDA
It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps prevent, both, acute and delayed phases of CINV
Two biopharmaceutical experts join SK bioscience to strengthen the future strategies
Subscribe To Our Newsletter & Stay Updated